Search results for "Osteogenesi"

showing 10 items of 144 documents

Differential Effects of Exercise on Tibial Shaft Marrow Density in Young Female Athletes

2013

Increased mechanical loading can promote the preferential differentiation of bone marrow mesenchymal stem cells to osteoblastogenesis, but it is not known whether long-term bone strength-enhancing exercise in humans can reduce marrow adiposity.Our objective was to examine whether bone marrow density (MaD), as an estimate of marrow adiposity 1) differs between young female athletes with contrasting loading histories and bone strengths and 2) is an independent predictor of bone strength at the weight-bearing tibia.Mid-tibial MaD, cortical area (CoA), total area, medullary area, strength strain index (SSI), and cortical volumetric bone mineral density (vBMD) (total, endocortical, midcortical, …

Adultmedicine.medical_specialtyAdolescentChemical PhenomenaMedullary cavityEndocrinology Diabetes and MetabolismAdipocytes WhiteClinical BiochemistryBone Marrow CellsContext (language use)BiochemistryWeight-BearingYoung AdultEndocrinologyBone DensityBone MarrowOsteogenesisInternal medicinemedicineHumansTibiaQuantitative computed tomographyExerciseAdiposityBone mineralOsteoblastsTibiabiologymedicine.diagnostic_testAthletesbusiness.industryBiochemistry (medical)Adolescent Developmentbiology.organism_classificationPeripheralEndocrinologymedicine.anatomical_structureAthletesFemaleDiaphysesBone marrowTomography X-Ray ComputedbusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.

2013

Osteoporosis is characterized by low bone mineral density and/or poor bone microarchitecture leading to an increased risk of fractures. The skeletal alterations in osteoporosis are a consequence of a relative deficit of bone formation compared to bone resorption. Osteoporosis therapies have mostly relied on antiresorptive drugs. An alternative therapeutic approach for osteoporosis is currently available, based on the intermittent administration of parathyroid hormone (PTH). Bone anabolism caused by PTH therapy is mainly accounted for by the ability of PTH to increase osteoblastogenesis and osteoblast survival. PTH and PTH-related protein (PTHrP)-an abundant local factor in bone- interact wi…

medicine.medical_specialtyOsteoporosisParathyroid hormoneBone healingBiochemistryBone resorptionBone remodelingOsteogenesisInternal medicinemedicineAnimalsHumansBone regenerationCell ProliferationReceptor Parathyroid Hormone Type 1PharmacologyBone mineralOsteoblastsBone Density Conservation Agentsbusiness.industryParathyroid Hormone-Related ProteinOsteoblastCell Differentiationmedicine.diseaseProtein Structure Tertiarymedicine.anatomical_structureEndocrinologyGene Expression RegulationParathyroid HormoneOsteoporosisFemalebusinesshormones hormone substitutes and hormone antagonistsSignal TransductionBiochemical pharmacology
researchProduct

Osteogenesis imperfecta: a clinical study of the first ten years of life.

1992

One hundred twenty-seven children with osteogenesis imperfecta (O.I.) were studied during the first 10 years of life. According to Sillence, 40 patients were assigned to type I, 39 to type III, and 48 to type IV O.I. Centiles for height, weight, and the annual number of fractures could be established for the different types of O.I. The development of the skeletal changes could be documented for the different forms of the disease. At birth, the skeletal changes were significantly more severe in type III than in type IV patients. During the first 10 years of life the number of fractures, extent of skeletal deformities, and growth retardation did not differ between types III and IV. Only fract…

Malemedicine.medical_specialtyDentinogenesis imperfectaEndocrinology Diabetes and MetabolismPoison controlShort statureBone and BonesClinical studyFractures BoneEndocrinologymedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesInsulin-Like Growth Factor IChildHemihypertrophyBone Developmentbusiness.industryBody WeightInfant NewbornInfantOsteogenesis Imperfectamedicine.diseaseBody HeightSurgeryRadiographyScoliosisOsteogenesis imperfectaMotor SkillsChild PreschoolOrthopedic surgeryKidney stonesFemalemedicine.symptombusinessCalcified tissue international
researchProduct

Collagen overglycosylation: a biochemical feature that may contribute to bone quality.

2005

Skeletal ability to resist mechanical stress is determined by bone amount and quality, which relies on macro- and micro-architecture, turnover, bone matrix, and mineralisation; the role of collagen has not been clearly elucidated. Numerous post-translational steps are involved in collagen type I biosynthesis, including residue hydroxylation and glycosylation catalysed by enzymes that work until the protein folds forming the triple helix; therefore, folding rate regulates these processes. Overglycosylated hydroxylysines are poor substrates for epsilon-amino group deamination which initiates cross-link formation. Three clinical conditions associated with fractures may relate collagen overglyc…

chemistry.chemical_classificationGlycosylationGlycosylationOsteoporosisBiophysicsDeaminationCell BiologyOsteogenesis Imperfectamedicine.diseaseBiochemistryBone and BonesHydroxylationPostmenopausechemistry.chemical_compoundEnzymeBiosynthesischemistryBiochemistryDiabetes Mellitus Type 2Osteogenesis imperfectamedicineHumansCollagenMolecular BiologyTriple helixBiochemical and biophysical research communications
researchProduct

Osteogenic commitment and differentiation of human mesenchymal stem cells by low‐intensity pulsed ultrasound stimulation

2018

Low-intensity pulsed ultrasound (LIPUS) as an adjuvant therapy in in vitro and in vivo bone engineering has proven to be extremely useful. The present study aimed at investigating the effect of 30 mW/cm(2) LIPUS stimulation on commercially available human mesenchymal stem cells (hMSCs) cultured in basal or osteogenic medium at different experimental time points (7d, 14d, 21d). The hypothesis was that LIPUS would improve the osteogenic differentiation of hMSC and guarantying the maintenance of osteogenic committed fraction, as demonstrated by cell vitality and proteomic analysis. LIPUS stimulation (a) regulated the balance between osteoblast commitment and differentiation by specific network…

Proteomics0301 basic medicineTime FactorsUltrasonic WaveTranscription FactorPhysiologyCellular differentiationClinical BiochemistryLow-intensity pulsed ultrasoundOsteogenesisProtein Interaction MapsStem Cell Nichemesenchymal stem cellCells CulturedProtein metabolic processproteomic analysiMesenchymal Stromal CellReverse Transcriptase Polymerase Chain ReactionOsteogenesiIntracellular Signaling Peptides and ProteinsCell DifferentiationOsteoblastproteomic analysisFlow CytometryCell biologyRUNX2Phenotypemedicine.anatomical_structureUltrasonic Wavesosteoblast differentiationosteogenic commitmentProtein Interaction MapHumanSignal TransductionHomeobox protein NANOGlow-intensity pulsed ultrasoundTime FactorCell SurvivalEnzyme-Linked Immunosorbent AssayBiology03 medical and health sciencesSOX2medicineHumansCell LineageMesenchymal stem cellProteomicMesenchymal Stem CellsCell Biology030104 developmental biologyGene Expression RegulationIntracellular Signaling Peptides and ProteinImmunologyTranscription FactorsJournal of Cellular Physiology
researchProduct

Immobilization of BMP‐2, BMP‐7 and alendronic acid on titanium surfaces: Adhesion, proliferation and differentiation of bone marrow‐derived stem cells

2019

This study analyzed the influence of titanium (TiO2 ) surface modifications with two osteogenic proteins (BMP-2, BMP-7) and an anti-osteoclastic drug (alendronic acid [AA]) on sandblasted/acid-etched (SLA) and plain TiO2 (PT) on cell adhesion, proliferation and differentiation (alkaline phosphatase [AP] and osteocalcin [OC]) of bone-marrow derived stem cells (BMSCs) after 1, 3 and 7 days in-vitro. Initially, AA surfaces showed the highest cell number and surface coverage. At day 3 and 7, BMP and AA-modified surfaces exhibited a significantly enhanced cell growth. For proliferation, at days 3 and 7, an enhancement on BMP-2, BMP-7 and AA-surfaces was seen. At day 7, SLA also showed a higher p…

Materials scienceSurface PropertiesBone Morphogenetic Protein 70206 medical engineeringBiomedical EngineeringBone Morphogenetic Protein 2Biocompatible MaterialsBone Marrow Cells02 engineering and technologyBone morphogenetic protein 2BiomaterialsOsteogenesisCell AdhesionmedicineHumansCell adhesionCells CulturedCell ProliferationTitaniumAlendronateBone Density Conservation AgentsbiologyCell growthStem CellsAlendronic acidfungiMetals and AlloysCell DifferentiationAdhesion021001 nanoscience & nanotechnology020601 biomedical engineeringMolecular biologyImmobilized Proteinsmedicine.anatomical_structureembryonic structuresCeramics and CompositesOsteocalcinbiology.proteinAlkaline phosphataseBone marrow0210 nano-technologymedicine.drugJournal of Biomedical Materials Research Part A
researchProduct

The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?

2009

Osteoporosis is a chronic disease that accelerates after menopause in many women. Most of the pharmacologic attempts to control the disease, such as hormone therapy, have emphasized the constraint of bone resorption. Since recent years have witnessed important advances in the field of bone formation, this review aims to update the present knowledge on the mechanisms affecting osteoblastogenesis and on the therapeutic results achieved by recently approved drugs.We sought peer-reviewed, full-length basic and clinical articles published between 1995 and May 2008 using a PubMed search strategy, with the terms osteoporosis and osteoblast, osteoporosis and strontium ranelate, and osteoporosis and…

medicine.medical_specialtyPediatricsmedicine.medical_treatmentOsteoporosisThiophenesDiseasePostmenopausal osteoporosisFractures BoneStrontium ranelateOsteogenesisOrganometallic CompoundsmedicineAnimalsHumansBone formationOsteoporosis PostmenopausalAgedOsteoblastsBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCell DifferentiationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryMenopauseChronic diseaseGene Expression RegulationParathyroid HormoneFemaleHormone therapybusinessmedicine.drugClimacteric
researchProduct

Distribution of osteonectin mRNA and protein during human embryonic and fetal development.

1992

We investigated the temporal and spatial distribution of osteonectin during human embryonic and fetal development, using in situ hybridization and immunohistochemistry. Osteonectin gene expression was generally found in cells exhibiting high rates of matrix production/proliferation. In mineralized tissue, a strong signal was obtained in osteoblasts, odontoblasts, and chondrocytes of the upper hypertrophic and proliferative zones. Chondrocytes of the mineralized zone showed no expression throughout the different stages of development. Strong osteonectin expression was found in odontoblasts of developing teeth. In addition, osteonectin mRNA and protein were detected in several non-mineralize…

medicine.medical_specialtyHistologyGene ExpressionIn situ hybridizationEmbryonic and Fetal DevelopmentFetusOsteogenesisPregnancyInternal medicineGene expressionmedicineExtracellularHumansOsteonectinRNA MessengerbiologyCartilageEmbryogenesismusculoskeletal systemEmbryo MammalianImmunohistochemistryCell biologyAbortion Spontaneousmedicine.anatomical_structureOdontoblastEndocrinologyOrgan Specificitybiology.proteinImmunohistochemistryFemaleAnatomyOsteonectinThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
researchProduct

Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.

2005

Abstract During embryogenesis the bone tissue of craniomandibular joint (CMJ) is formed through two pathways: intramembranous ossification and endochondral ossification. The development process is under the control of regulatory factors.The osteoprotegerin (OPG) and the receptor activator of nuclear factor (NF)-κB ligand are key regulators of osteoclastogenesis. The aim of this study is the localization of OPG and RANKL mRNA and protein in the foetal CMJ by immunohistochemistry (IHC) and in situ hybridization (ISH). The main results were: OPG and RANKL mRNA and protein were co-localized in the same cell types; OPG and RANKL were specially immunolocated in osteogenic cells; immunolabeling wa…

musculoskeletal diseasesCartilage Articularmedicine.medical_specialtyReceptors Cytoplasmic and NuclearIn situ hybridizationBiologyBone tissueReceptors Tumor Necrosis FactorBone remodelingOsteoprotegerinOsteogenesisInternal medicineBone cellmedicineHumansRNA MessengerEndochondral ossificationIn Situ HybridizationGlycoproteinsMembrane GlycoproteinsReceptor Activator of Nuclear Factor-kappa BTemporomandibular JointRANK LigandOsteoprotegerinCell BiologyGeneral MedicineImmunohistochemistryCell biologyEndocrinologymedicine.anatomical_structureRANKLIntramembranous ossificationbiology.proteinCarrier ProteinsDevelopmental BiologyTissuecell
researchProduct

Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

2005

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S-CTX, U-DPD, S-PINP, S-BALP, and S-OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal-to-noise ratio than the other markers. INTRODUCTION: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S-TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. MATERIALS AND METHODS: This double-blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n=75) and the other receiving placebo …

medicine.medical_specialtyDeoxypyridinolineEndocrinology Diabetes and MetabolismAcid PhosphataseUrologyPlaceboBone resorptionBone remodelingchemistry.chemical_compoundDouble-Blind MethodOsteogenesisInternal medicinemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineVitamin DAlendronateBone Density Conservation AgentsReceiver operating characteristicbiologyTartrate-Resistant Acid Phosphatasebusiness.industryAlendronic acidMiddle AgedIsoenzymesPostmenopauseEndocrinologychemistryOsteocalcinbiology.proteinCalciumFemaleDrug MonitoringbusinessBiomarkersmedicine.drugJournal of Bone and Mineral Research
researchProduct